{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:04:16Z","timestamp":1793225056203,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T00:00:00Z","timestamp":1365465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Cereblon (<jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic>) has recently been identified as a target for immunomodulatory drugs (<jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>i<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>s) and its downregulation has been linked to resistance to lenalidomide. Here, we studied <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> expression by real time polymerase chain reaction in 49 bone marrow samples of newly diagnosed patients with multiple myeloma treated with lenalidomide and dexamethasone. Median <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> expression was 3\u00b745 in patients who achieved complete response, and 3\u00b775, 2\u00b701, 0\u00b778, and 0\u00b770 in those with very good partial response, partial response, stable disease and progressive disease respectively. <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> expression levels correlated significantly with response to lenalidomide treatment (<jats:italic>r<\/jats:italic>\u00a0=\u00a00\u00b748; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001). Among established prognostic parameters, only beta\u20102\u2010microglobulin correlated with cereblon (<jats:italic>r<\/jats:italic>\u00a0=\u00a00\u00b766; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001). A close association of <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> with interferon regulatory factor 4 (<jats:italic><jats:styled-content style=\"fixed-case\">IRF<\/jats:styled-content>4<\/jats:italic>) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001) and with <jats:italic><jats:styled-content style=\"fixed-case\">CTNNB<\/jats:styled-content>1<\/jats:italic> (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001) was found. Overall, a statistically significant association between baseline <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> expression and response in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> patients treated with lenalidomide is shown. <jats:italic><jats:styled-content style=\"fixed-case\">CRBN<\/jats:styled-content><\/jats:italic> expression is closely associated with <jats:italic><jats:styled-content style=\"fixed-case\">IRF<\/jats:styled-content>4<\/jats:italic>, which is an important target of <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>i<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content> therapy.<\/jats:p>","DOI":"10.1111\/bjh.12338","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T10:16:59Z","timestamp":1365502619000},"page":"695-700","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["High expression of cereblon (<i><scp>CRBN<\/scp><\/i>) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone"],"prefix":"10.1111","volume":"161","author":[{"given":"Daniel","family":"Heintel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rocci","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia dell'Universit\u00e0 di Torino Azienda Ospedaliera S. Giovanni Battista Ospedale Molinette Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Bolomsky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Caltagirone","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia dell'Universit\u00e0 di Torino Azienda Ospedaliera S. Giovanni Battista Ospedale Molinette Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[{"name":"Division of Haematology and Haemostaseology Department of Medicine I Medical University of Vienna (MUW) Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Haematology Wilhelminenspital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Division of Haematology and Haemostaseology Department of Medicine I Medical University of Vienna (MUW) Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia dell'Universit\u00e0 di Torino Azienda Ospedaliera S. Giovanni Battista Ospedale Molinette Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.10.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.180208"},{"key":"e_1_2_7_4_1","first-page":"624","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"124","author":"Broyl A.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_5_1","first-page":"287","article-title":"What is the functional role of the thalidomide binding protein cereblon?","volume":"2","author":"Chang X.B.","year":"2011","journal-title":"International Journal of Biochemistry and Molecular Biology"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802627903"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403294"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404895"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0619-9"},{"key":"e_1_2_7_14_1","first-page":"931","article-title":"High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide","volume":"120","author":"Klimowicz A.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-011-0077-y"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314278"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08689.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.567265"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1845"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152011795347487"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802005191"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140954"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-356063"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12338","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.12338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:27:48Z","timestamp":1692671268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/bjh.12338"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12338","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,9]]},"assertion":[{"value":"2012-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}